Active	Status	Sponsor type	Region	Phase	Filter
2 Active 4 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Huang, Yiran
NCT04568304: A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma	Not yet recruiting	3	364	RoW	Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection, Placebo	Shanghai Junshi Bioscience Co., Ltd.	Locally Advanced or Metastatic Urothelial Carcinoma	11/23	11/25
NCT05831891: Fruquintinib and SeRplulimab: Opening New Frontiers in Treating Non-clear Cell Renal Cell Carcinoma Dec 2024 - Dec 2024 : Safety and efficacy data for 1L adv nccRCC	Recruiting	2	39	RoW	Fruquintinib combined with Serplulimab, Elunate, HLX10	RenJi Hospital, Shanghai Zhongshan Hospital	Non-clear Renal Cell Carcinoma	06/25	07/26
Chen, Yonghui
No trials found